Skip to main content

Table 2 Confirmed objective responses

From: Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Response 1 L (n = 62) 2 L (n = 20)
Best overall response, n (%)
 Complete response 1 (1.6) 0
 Partial response 9 (14.5) 2 (10.0)
 Stable disease 38 (61.3) 13 (65.0)
 Progressive disease 11 (17.7) 4 (20.0)
 Not evaluable 3 (4.8)a 1 (5.0)b
Objective response rate (95% CI), % 16.1 (8.0–27.7) 10.0 (1.2–31.7)
Disease control rate, % 77.4 75.0
Response duration 1 L (n = 10) 2 L (n = 2)
Median duration of response (95% CI), months 9.9 (2.8–NE) NE (6.9–NE)
Proportion of patients with specified duration of response (95% CI), %c
 6 months 60.0 (25.3–82.7) 100.0 (NE)
 12 months 30.0 (7.1–57.8) 50.0 (0.6–91.0)
  1. a Due to no postbaseline assessment (n = 2) or stable disease of insufficient duration (< 6 weeks after start date without further tumor assessment; n = 1)
  2. b All postbaseline assessments not evaluable (n = 1)
  3. c Based on Kaplan-Meier estimates
  4. 1 L first-line subgroup, 2 L second-line subgroup, CI confidence interval, NE not evaluable